Pharvaris N.V.

$29.45+1.73%(+$0.50)
TickerSpark Score
54/100
Mixed
53
Valuation
20
Profitability
15
Growth
84
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHVS research report →

52-Week Range78% of range
Low $15.46
Current $29.45
High $33.33

Companypharvaris.com

Pharvaris N. V. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.

CEO
Berndt Axel Edvard Modig
IPO
2021
Employees
108
HQ
Leiden, NL

Price Chart

+70.72% · this period
$32.94$24.20$15.46May 20Nov 18May 20

Valuation

Market Cap
$1.93B
P/E
-9.77
P/S
0.00
P/B
6.99
EV/EBITDA
-8.30
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-67.38%
ROIC
-72.74%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-175,699,397 · -30.90%
EPS
$-2.97 · -19.76%
Op Income
$-169,822,932
FCF YoY
-13.73%

Performance & Tape

52W High
$33.33
52W Low
$15.46
50D MA
$28.35
200D MA
$25.53
Beta
-2.33
Avg Volume
258.61K

Get TickerSpark's AI analysis on PHVS

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
May 15, 26Glassman Robertother5,333
May 15, 26Glassman Robertsell5,333
May 15, 26Glassman Robertsell4,667
May 15, 26Glassman Robertother5,333
May 15, 26Abele Stefan Andreassell8,748
May 15, 26Souverijns Wimsell10,000
May 11, 26Lu Pengother109
May 12, 26Lu Pengother117
May 1, 26Lu Pengother14,023
May 1, 26Lu Pengother143

Our PHVS Coverage

We haven't published any research on PHVS yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate PHVS Report →

Similar Companies